Translational Genetics and Genomics Unit
https://www.niams.nih.gov/labs/ombrello-lab
Led by Dr. Michael Ombrello, the unit uses genomic approaches to understand the underlying factors of autoinflammatory and rheumatic diseases.
Enter a phrase above to search files and articles within the site.
Typically materials that are more than 5 years old will be archived
Displaying 1 - 15 of 15 results
Alopecia Areata
https://www.niams.nih.gov/health-topics/alopecia-areata
What is alopecia areata? Alopecia areata is a disease that causes hair loss. In alopecia areata, the immune system attacks the structures in skin that form hair (hair follicles). Alopecia areata usually affects the head and face, though hair can be lost from any part of the body. Hair typically falls out in small, round patches about the size of a quarter. In some cases, hair loss is more extensive.
Mariana J. Kaplan, M.D.
https://www.niams.nih.gov/about/directory/mariana-j-kaplan-md
Dr. Kaplan’s research focuses on identifying the molecular mechanisms that promote the initiation and perpetuation of perturbed immune responses and the development of organ damage and premature vascular disease in systemic autoimmunity.
Yongquan Luo, Ph.D.
https://www.niams.nih.gov/about/directory/yongquan-luo-phd
Dr. Yongquan Luo is a biologist in the Pediatric Translational Research Branch. He is pursuing studies of mutation of gene WHAMM on pathogenesis in Axial spondyloarthritis using patient derived hiPSCs and CRISPR/Cas9 technologies.
Reactive Arthritis
https://www.niams.nih.gov/health-topics/reactive-arthritis
What is reactive arthritis? Reactive arthritis happens when an infection causes joint pain and swelling. A bacterial infection in the digestive or urinary tract or the genitals usually triggers the condition, but arthritis symptoms typically do not start until a few weeks after you have recovered from the infection. The most common features of reactive arthritis are inflammation of the joints (especially the knees and ankles), eyes, and urinary tract, but not everyone gets all three, or they might not happen at the same time.
Osteoarthritis
https://www.niams.nih.gov/health-topics/osteoarthritis
What is osteoarthritis? Osteoarthritis is a joint disease that happens when the tissues in the joint break down over time. It is the most common type of arthritis and is more common in older people. People with osteoarthritis usually have joint pain and, after rest, stiffness (inability to move easily) for a short period of time. The most commonly affected joints include the: Hands (ends of the fingers and at the base and ends of the thumbs). Knees. Hips. Neck. Lower back. Osteoarthritis affects each person differently. For some people, osteoarthritis does not affect day-to-day activities. For others, it causes
Pemphigus
https://www.niams.nih.gov/health-topics/pemphigus
What is pemphigus? Pemphigus is a rare disease that causes blistering on many parts of the body, including the skin and the inside of the mouth, nose, throat, eyes, and genitals. In pemphigus, the immune system mistakenly attacks cells in the top layer of the skin.
Paget’s Disease of Bone
https://www.niams.nih.gov/health-topics/pagets-disease-bone
What is Paget’s disease? Paget’s disease of bone is a chronic (long-lasting) disorder that causes bones to grow larger and become weaker than normal. Usually only one or a few bones have the disease. Many people with Paget’s disease do not have symptoms. However, the bone changes can cause: Bone pain. Misshapen bones. Broken bones (fractures). Problems in the joints near the bones with the disease. With treatment, many people can: Manage their symptoms. Improve pain. Control the effects of the disease.
Gout
https://www.niams.nih.gov/health-topics/gout
What is gout? Gout is a type of arthritis that causes pain and swelling in your joints, usually as flares that last for a week or two, and then go away. Gout flares often begin in your big toe or a lower limb. Gout happens when high levels of a substance called serum urate build up in your body. When this happens, needle-shaped crystals form in and around the joint. This leads to inflammation and arthritis of the joint. However, many people with high levels of serum urate will not develop gout. With early diagnosis, treatment, and lifestyle changes, gout
Close to home: NIH researcher and alopecia patient seeks a cure
https://www.niams.nih.gov/close-home-nih-researcher-and-alopecia-patient-seeks-cure
Engineered cartilage produces anti-inflammatory drug
https://www.niams.nih.gov/engineered-cartilage-produces-anti-inflammatory-drug
Machine learning detects early signs of osteoarthritis
https://www.niams.nih.gov/machine-learning-detects-early-signs-osteoarthritis
Health Disparities in Osteoarthritis Workshop - July 2022
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA), and National Institute on Minority Health and Health Disparities (NIMHD) are sponsoring a virtual workshop on Health Disparities in Osteoarthritis on Tuesday, July 12 – Wednesday, July 13, 2022, starting at 11:00 AM (ET) each day. The workshop will focus on combining behavioral and biomedical science to address personal, interpersonal, and societal influences that contribute to health disparities in osteoarthritis. Discussions will cover how understanding these disparities can lead to better health in osteoarthritis. Please visit the NIH Health Disparities in Osteoarthritis Workshop page
Recharging cartilage after knee damage
https://www.niams.nih.gov/recharging-cartilage-after-knee-damage
NIBIB-funded researchers are developing an implantable, biodegradable film that helps to regenerate the native cartilage at the site of damage. Their study, performed in rabbits, could be an initial, important step in the establishment of a new treatment for this common condition, osteoarthritis.
FDA Approves First Systemic Treatment for Alopecia Areata
https://www.niams.nih.gov/fda-approves-first-systemic-treatment-alopecia-areata
The FDA approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata. The action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata.